Probenecid Arrests the Progression of Pronounced Clinical Symptoms in a Mouse Model of Multiple Sclerosis

Overview

Journal Sci Rep

Specialty Science

Date 2017 Dec 10

PMID 29222419

Citations 14

Authors

Nadine Hainz

Sandra Wolf

Artjom Beck

Stefan Wagenpfeil

Thomas Tschernig

Carola Meier

Affiliations

Soon will be listed here.

Abstract

While it has been established that Probenecid (PBN) prevents the onset of experimental autoimmune encephalomyelitis (EAE) in mice, it is not clear whether it has any effect on already manifest EAE. The aim of this study was therefore to analyze the therapeutic effect of PBN in pronounced EAE. Mice with manifest clinical symptoms of EAE were either treated with PBN or solvent for 20 days, or they were left untreated. The clinical symptoms were monitored daily. Inflammation, demyelination and oligodendrocyte numbers were determined in the spinal cord. We were able to demonstrate that PBN not only significantly prolonged survival but also prevented the progression of clinical symptoms in the EAE model of multiple sclerosis. In addition, we were able to show that PBN reduced inflammation, T cell infiltration and oligodendrocyte cell loss. PBN was previously shown to inhibit - among other targets - pannexin channels. As pannexin channels provide conduits for ATP, are associated with the inflammasome, and act as "find me-signals" in the process of apoptosis, inhibition of pannexins via PBN might contribute to the PBN-effects observed in this study. The beneficial and therapeutic effects of PBN in the context of EAE demonstrate an intriguing link between PBN and neuroinflammation, which might foster translational interest.

Citing Articles

Microglial Mayhem NLRP3 Inflammasome's Role in Multiple Sclerosis Pathology.

Fan H, Fu Q, Du G, Qin L, Shi X, Wang D CNS Neurosci Ther. 2024; 30(12):e70135.

PMID: 39690733 PMC: 11652677. DOI: 10.1111/cns.70135.

Mitochondrial Dysfunction is a Crucial Immune Checkpoint for Neuroinflammation and Neurodegeneration: mtDAMPs in Focus.

Mishra Y, Kumar A, Kaundal R Mol Neurobiol. 2024; .

PMID: 39115673 DOI: 10.1007/s12035-024-04412-0.

Probenecid, an Old Drug with Potential New Uses for Central Nervous System Disorders and Neuroinflammation.

Garcia-Rodriguez C, Mujica P, Illanes-Gonzalez J, Lopez A, Vargas C, Saez J Biomedicines. 2023; 11(6).

PMID: 37371611 PMC: 10295187. DOI: 10.3390/biomedicines11061516.

Probenecid affects muscle Ca2+ homeostasis and contraction independently from pannexin channel block.

Jaque-Fernandez F, Allard B, Monteiro L, Lafoux A, Huchet C, Jaimovich E J Gen Physiol. 2023; 155(4).

PMID: 36820799 PMC: 9998970. DOI: 10.1085/jgp.202213203.

Neurodegeneration in Multiple Sclerosis: The Role of Nrf2-Dependent Pathways.

Maldonado P, Guevara C, Olesen M, Orellana J, Quintanilla R, Ortiz F Antioxidants (Basel). 2022; 11(6).

PMID: 35740042 PMC: 9219619. DOI: 10.3390/antiox11061146.

References

Bao L, Locovei S, Dahl G . Pannexin membrane channels are mechanosensitive conduits for ATP. FEBS Lett. 2004; 572(1-3):65-8. DOI: 10.1016/j.febslet.2004.07.009. View

Hainz N, Wolf S, Tschernig T, Meier C . Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis. Inflammation. 2015; 39(1):123-128. DOI: 10.1007/s10753-015-0230-1. View

Wolf S, Hainz N, Beckmann A, Maack C, Menger M, Tschernig T . Brain damage resulting from postnatal hypoxic-ischemic brain injury is reduced in C57BL/6J mice as compared to C57BL/6N mice. Brain Res. 2016; 1650:224-231. DOI: 10.1016/j.brainres.2016.09.013. View

Adamson S, Leitinger N . The role of pannexin1 in the induction and resolution of inflammation. FEBS Lett. 2014; 588(8):1416-22. PMC: 4060616. DOI: 10.1016/j.febslet.2014.03.009. View

Ligon K, Alberta J, Kho A, Weiss J, Kwaan M, Nutt C . The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. 2004; 63(5):499-509. DOI: 10.1093/jnen/63.5.499. View

Coll R, Robertson A, Chae J, Higgins S, Munoz-Planillo R, Inserra M . A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015; 21(3):248-55. PMC: 4392179. DOI: 10.1038/nm.3806. View

Jian Z, Ding S, Deng H, Wang J, Yi W, Wang L . Probenecid protects against oxygen-glucose deprivation injury in primary astrocytes by regulating inflammasome activity. Brain Res. 2016; 1643:123-9. DOI: 10.1016/j.brainres.2016.05.002. View

Silverman W, Locovei S, Dahl G . Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol. 2008; 295(3):C761-7. PMC: 2544448. DOI: 10.1152/ajpcell.00227.2008. View

Davalos D, Grutzendler J, Yang G, Kim J, Zuo Y, Jung S . ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005; 8(6):752-8. DOI: 10.1038/nn1472. View

10.

Schenk U, Westendorf A, Radaelli E, Casati A, Ferro M, Fumagalli M . Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal. 2008; 1(39):ra6. DOI: 10.1126/scisignal.1160583. View

11.

Shin Y, Lee J, Oh J, Lee Y . Low-dose probenecid selectively inhibits urinary excretion of phenolsulfonphthalein in rats without affecting biliary excretion. J Appl Toxicol. 2011; 33(6):511-5. DOI: 10.1002/jat.1778. View

12.

Lohman A, Leskov I, Butcher J, Johnstone S, Stokes T, Begandt D . Pannexin 1 channels regulate leukocyte emigration through the venous endothelium during acute inflammation. Nat Commun. 2015; 6:7965. PMC: 4824045. DOI: 10.1038/ncomms8965. View

13.

Chekeni F, Elliott M, Sandilos J, Walk S, Kinchen J, Lazarowski E . Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature. 2010; 467(7317):863-7. PMC: 3006164. DOI: 10.1038/nature09413. View

14.

Wei R, Wang J, Xu Y, Yin B, He F, Du Y . Probenecid protects against cerebral ischemia/reperfusion injury by inhibiting lysosomal and inflammatory damage in rats. Neuroscience. 2015; 301:168-77. DOI: 10.1016/j.neuroscience.2015.05.070. View

15.

Endong L, Shijie J, Sonobe Y, Di M, Hua L, Kawanokuchi J . The gap-junction inhibitor carbenoxolone suppresses the differentiation of Th17 cells through inhibition of IL-23 expression in antigen presenting cells. J Neuroimmunol. 2011; 240-241:58-64. DOI: 10.1016/j.jneuroim.2011.09.012. View

16.

Castro-Borrero W, Graves D, Frohman T, Flores A, Hardeman P, Logan D . Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2012; 5(4):205-20. PMC: 3388530. DOI: 10.1177/1756285612450936. View

17.

van der Star B, Vogel D, Kipp M, Puentes F, Baker D, Amor S . In vitro and in vivo models of multiple sclerosis. CNS Neurol Disord Drug Targets. 2012; 11(5):570-88. DOI: 10.2174/187152712801661284. View

18.

Hainz N, Becker P, Rapp D, Wagenpfeil S, Wonnenberg B, Beisswenger C . Probenecid-treatment reduces demyelination induced by cuprizone feeding. J Chem Neuroanat. 2017; 85:21-26. DOI: 10.1016/j.jchemneu.2017.06.003. View

19.

Ontaneda D, Hyland M, Cohen J . Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med. 2011; 63:389-404. DOI: 10.1146/annurev-med-042910-135833. View

20.

Burma N, Bonin R, Leduc-Pessah H, Baimel C, Cairncross Z, Mousseau M . Blocking microglial pannexin-1 channels alleviates morphine withdrawal in rodents. Nat Med. 2017; 23(3):355-360. DOI: 10.1038/nm.4281. View